Tiotropium
نویسندگان
چکیده
منابع مشابه
Tiotropium bromide
Therapy with bronchodilators forms the pharmacologic foundation of the treatment of patients with COPD. Bronchodilators can significantly lessen dyspnea, increase airflow, improve quality of life, and enhance exercise performance. While bronchodilators decrease airway resistance and lessen dynamic hyperinflation in patients with COPD, they have not been shown to alter the rate of decline in FEV...
متن کاملTiotropium in paediatric asthma.
The emerging evidence that there are many types of asthma that may respond differently to treatment suggests a need for novel inhaled therapies beyond the current armamentarium of short-acting β2-agonists, long-acting β2-agonists (LABA) and inhaled corticosteroids (ICS). Recent phase III trials suggest that tiotropium, a long-acting muscarinic antagonist, is a promising treatment for adult asth...
متن کاملTiotropium Bromide: An Update
Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption and its very low systemic bioavailability. The drug is mainly indicated in COPD patients. Clinically relevant outcomes such as significant improvements in spirometry...
متن کاملTiotropium Bromide/Olodaterol (Stiolto Respimat)
INTRODUCTION Chronic obstructive pulmonary disease (COPD), a relatively common respiratory disorder in the U.S., is the third leading cause of death in this country.1 It has been estimated that 15 million Americans have COPD.1 Since the disorder is so common, effective treatment regimens are a prominent research topic in pharmacology. Still, the development of pharmacological treatments for COP...
متن کاملAnti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD.
The anti-inflammatory effects of salmeterol/fluticasone (SFP), tiotropium/fluticasone (Tio+FP) and tiotropium (Tio) alone were investigated on the inflammatory cells and mediators in sputum induced from chronic obstructive pulmonary disease patients. Subjects were either newly diagnosed or had not taken any medication for 3 months prior to the study. Subjects (n = 99) were randomised (not doubl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: pharma-kritik
سال: 2003
ISSN: 1010-5409
DOI: 10.37667/pk.2003.78